If resTORbio decides to fund and carry out the development or commercialization activities itself, resTORbio may require additional expertise and capital that may not be available under acceptable conditions or not at all available. If resTORbio does not cooperate and does not have sufficient resources or know-how to carry out the necessary development and commercialization activities, resTORbio may not be able to develop or market its product candidates, and resTORbios` activities may be seriously and detrimental. The merger agreement provides that resTORbio, the representative of the holders (as defined) and the rights representative (as defined therein) at the time of the merger, any share of the adicet share capital that is pending and executed immediately before the date of entry into force of the merger, excluding shares in the share capital of Adicet held in own shares and shares held by shareholders of Adicet, who have exercised and perfected the valuation The rights are converted into the right to obtain approximately 0.8555 common shares of resTORbio, subject to adjustment to account for the fraction of shares reversed in the range between 1-to-4 and 1-for-12. . . .